Timber Pharmaceuticals Inc

Timber Pharmaceuticals — Investor Presentation (February 2023)

37 slides from Timber Pharmaceuticals's investor presentation, Feb 3, 2023

  1. Slide 1: Corporate Overview February 2023

    NYSE American: TMBR Corporate Overview February 2023

  2. Slide 2: Safe Harbor Statement

    NYSE American: TMBR Safe Harbor Statement 2 Certain statements contained in this PowerPoint presentation describing Timber’s technology and development program, including, without limitation, statements containing the words “expects,” “anticipates,” “believes,” and words of similar import, constitut

  3. Slide 3: Specialty pharmaceutical company for rare dermatologic diseases

    NYSE American: TMBR 3 Timber Pharmaceuticals is a specialty pharmaceutical company devoted to transforming the lives of patients with rare, high impact dermatologic diseases by utilizing advanced translational science ..

  4. Slide 4: Business Strategy in Rare Dermatologic Diseases

    NYSE American: TMBR Timber Business Strategy in Rare Dermatologic Diseases 4 Focused on Orphan Drug Indications and Leveraging the 505(b)(2) pathway • Timber can be first to market by pursuing conditions for which there are no current FDA approved treatments • Requires potentially smaller and less c

  5. Slide 5: Investment Highlights

    NYSE American: TMBR Investment Highlights 5 • Positioning to become a leading rare disease dermatology company with a focus on rare and orphan dermatologic diseases, led by a management team with a proven track record in development and commercialization • Lead product candidate TMB - 001 has achiev

  6. Slide 6: Product pipeline by indication and phase

    Product/Indication TMB - 001 (topical isotretinoin) Congenital ichthyosis 1 TMB - 003 ( topical Sitaxsentan ) Sclerotic skin d iseases 2 1 Indications under consideration include Darier’s Disease, Severe Acne and/or Sebaceous Hyperplasia 2 Initially to be investigated in Lichen Sclerosis; additional

  7. Slide 7: Topical Isotretinoin Program targeting Congenital Ichthyosis

    NYSE American: TMBR 7 7 NYSE American: TMBR TMB - 001 – Topical Isotretinoin Phase 3 Program targeting Moderate to Severe Congenital Ichthyosis (CI)

  8. Slide 8: Congenital Ichthyosis: rare disorder with no FDA approved treatments

    NYSE American: TMBR 8 8 NYSE American: TMBR TMB - 001 – Topical Isotretinoin Phase 3 Asset targeting Moderate to Severe Congenital Ichthyosis (CI) 2017 Yale Copyright Congenital Ichthyosis is a rare disorder of keratinization affecting ~ 80,000 people in the U.S. and >1.5 million globally Quality of

  9. Slide 9: Topical Isotretinoin in CI

    NYSE American: TMBR 9 TMB - 001 - Topical Isotretinoin in CI Patented topical formulation that minimizes systemic absorption, thereby allowing for chronic treatment  Isotretinoin is well known as the most effective therapy for several skin conditions, including ichthyosis, but it is not approved fo

  10. Slide 10: Drug Substance and Drug Product Safety and Efficacy

    NYSE American: TMBR 10  Drug Substance Safety and Efficacy • Tretinoin and Acitretin: narrower therapeutic window than isotretinoin, issues with ethanol conversion of acitretin; prolonged (2 - 3 year) hepatic storage • Isotretinoin: 5 biologically active metabolites gives broader spectrum of activi

  11. Slide 11: Phase 2a Proof of Concept Trial in CI

    NYSE American: TMBR 11 • Randomized, double - blind, placebo controlled, bilateral comparison (e.g., left arm vs. right arm) in ages 12 and up • 19 patients; area of treatment > 150 cm², each area < 6% Body Surface Area (BSA) (treatment no more than 12% BSA) • 0.1% and 0.2% strengths of TMB - 001 •

  12. Slide 12: Pharmacokinetics - Phase 2a Trial

    NYSE American: TMBR 12 Pharmacokinetics - Phase 2a Trial • Small number of subjects • Very low systemic absorption over 90 - day study period. • Only representative of 6 - 12% BSA application; maximal use study (n=32) will require subjects demonstrate 75 - 90% BSA involvement. • Modeling supports ma

  13. Slide 13: Phase 2b CONTROL study design

    NYSE American: TMBR 1 Marukian NV, et al. J Invest Dermatol. 2017; 137:1834 - 41. *VIIS - 50 was defined as ≥50% reduction relative to baseline in the sum of scores for VIIS scaling target sites that had baseline scores ≥3. AE, adverse event; ARCI - LI, autosomal recessive CI - lamellar ichthyosis;

  14. Slide 14: Patient story: NJ.com article

    “They called him ‘Lizard Skin.’ Now he’s a N.J. med student confronting the condition that haunted him.” “…entered a phase 2b clinical trial by Timber Pharmaceuticals in the hopes of finding a new treatment. He said he experienced ‘almost a night and day difference after using their topical ointment

  15. Slide 15: CONTROL Study - Efficacy Per Protocol

    NYSE American: TMBR 15 TMB - 001 CONTROL Study - Efficacy Per Protocol 100% of the Per Protocol Population in 0.05% dose achieved a 50% reduction in VIIS score versus 40% in the vehicle group (nominal p=.04) 100% of the Per Protocol Population in 0.05% dose achieved a 2 point reduction in IGA versus

  16. Slide 16: CONTROL Study - Efficacy Intent to Treat

    NYSE American: TMBR 16 TMB - 001 CONTROL Study - Efficacy Intent to Treat (ITT) 64% of the ITT Population in 0.05% dose achieved a 50% reduction in VIIS score versus 33% in the vehicle group (nominal p=.17) 55% of the ITT Population in 0.05% dose achieved a 2 point reduction in IGA versus. 8% in the

  17. Slide 17: Phase 2b CONTROL: Lamellar Ichthyosis (TGM1) responder

    NYSE American: TMBR Baseline VIIS 4 V6 EOS VIIS 2 TMB - 001 – Phase 2b CONTROL study Lamellar Ichthyosis (TGM1) 39 year old patient - 0.05% treatment arm (responder)

  18. Slide 18: Phase 2b CONTROL: Lamellar Ichthyosis (ALOX12B) responder

    NYSE American: TMBR TMB - 001 – Phase 2b CONTROL study Lamellar Ichthyosis (ALOX12B) 21 year old patient - 0.05% treatment arm (responder) EOS V6 - lower leg Baseline - lower leg

  19. Slide 19: Phase 2b CONTROL: X-Linked Ichthyosis responder

    NYSE American: TMBR TMB - 001 – Phase 2b CONTROL study X - Linked Ichthyosis 54 year old patient - 0.05% treatment arm (responder) EOS V6 - right foot Baseline - right foot

  20. Slide 20: Local Skin Reactions

    NYSE American: TMBR Local Skin Reactions Four most expected skin reactions were continuously evaluated : Burning/Stinging, Erythema, Edema and Erosions TMB - 001 – Phase 2b CONTROL study Local Skin reactions • The four most expected skin reactions were continuously evaluated: Burning/Stinging, Eryth

  21. Slide 21: Patient story: The Republican article

    “He knows who he is’: Agawam’s Peyton Fleagle raises awareness for rare skin condition.” Article by Cori Urban The Republican published 12/15/2022 “..as for the trial, ‘it was like magic for Peyton,’ Fleagle continued. The first few weeks were difficult as Peyton’s skin did get worse before it got b

  22. Slide 22: Key Lessons Learned from Phase 2b

    NYSE American: TMBR Local Skin Reactions IGA primary endpoint Induction period of QD + emollient LSR Management Ages 6 and above, X - linked and ARCI (9 different genotypes) Assessing Severity Both VIIS - 50 and IGA > 2 point improvement indicate improvement with TMB - 001; improvements in VIIS and

  23. Slide 23: Anticipated Regulatory Milestones to U.S. Launch

    NYSE American: TMBR First Subject Consented to the Study. Phase 3 study start Last Subject randomized Enrollment end Last Subject Last Visit Study end Database Lock and Key Endpoint Results Top - line data Final document sent from rolling submission Final NDA Submission 6 months following Priority R

  24. Slide 24: ASCEND Study

    Ha 4 Pact) ro Po ASCEND STUDY

  25. Slide 25: ASCEND: Study Design

    NYSE American: TMBR ASCEND: Study Design 25 TMB - 001 – Phase 3 ASCEND study N=142 subjects (110 in main study, 32 in Maximal Use Study)

  26. Slide 26: Key Efficacy Measurements

    NYSE American: TMBR Key Efficacy Measurements Notable Endpoint Changes from Phase 2b Trial • FDA requirement of both scaling and fissuring sub - scores. • The differences in proportions of subjects with >4 - point improvement from baseline in Worst Itch - Quality of Life (QoL) scores at Week 12 in s

  27. Slide 27: Multiple Barriers to Entry

    NYSE American: TMBR Multiple Barriers to Entry 27  Orphan exclusivity granted for all three strategic assets  Patents granted and pending globally  Trade secrets in formulation/manufacturing • Cytotoxic, requires containment, photolabile, prone to oxidation, temperature sensitivities, stability c

  28. Slide 28: Market opportunity and key considerations

    NYSE American: TMBR TMB - 001 – Market opportunity Key considerations Confidential Timber Pharmaceuticals, LLC 28 • Annual peak* U.S. sales conservatively estimated at $250 million for the CI indication by Year 5 • Targeted commercial approach • Target physicians focused at major academic centers •

  29. Slide 29: TMB-003 Topical Sitaxsentan Sclerotic Skin Diseases

    NYSE American: TMBR 29 29 NYSE American: TMBR TMB - 003 - Topical Sitaxsentan Sclerotic Skin Diseases

  30. Slide 30: TMB-003 Topical Sitaxsentan: Highly Selective ET-A inhibitor

    NYSE American: TMBR 30 TMB - 003 Topical Sitaxsentan for Sclerotic Skin Diseases Highly Selective ET - A inhibitor  Sitaxsentan is a highly selective (6,500:1) ET - A receptor antagonist. • It was previously on the market in the E.U., Canada and Australia as an oral treatment for PAH but was volunt

  31. Slide 31: Lichen Sclerosis

    NYSE American: TMBR 31 Lichen Sclerosis Rare chronic disease of vulvae and perianal areas which affects approximately 160,000 women in the U.S.*  Lichen Sclerosis affects both sexes, but is predominant in women • Prevalence 0.1 - 1.7% of women; diagnosed more by gynecologists than dermatologists •

  32. Slide 32: Scleroderma

    NYSE American: TMBR 32 Scleroderma Rare connective tissue disorder characterized by abnormal thickening of the skin  Two potential markets: • Moderate to Severe Localized Scleroderma which generally only affects the skin • More common in children, with a prevalence of approximately 90,000 people in

  33. Slide 33: Management team: Koconis and Mendelsohn

    NYSE American: TMBR John Koconis, MBA, Chairman and CEO • Seasoned Pharmaceutical executive with over 25 years experience leading successful teams in global markets and having launche d multiple market leading products in Dermatology • President & CEO of LEO Pharma (U.S.), established a market leadi

  34. Slide 34: Management team: Lucchese and Bruno-Raiz

    NYSE American: TMBR Joseph Lucchese, CFO • Chief Financial Officer of Timber Pharmaceuticals • Founding member and Managing Director of Oncology Partners; Managing Director at BlueStone Capital Partners, headed the Private Placement desk • Portfolio Manager and Chief Financial Officer of the MicroCa

  35. Slide 35: Independent Board of Directors

    NYSE American: TMBR Independent Board of Directors 35 Lead Independent Board Member Respected expert in SEC reporting and internal controls with extensive financial leadership experience as CFO at several public life sciences companies. Independent Board Member Professor of Dermatology at New York U

  36. Slide 36: Key Takeaways

    NYSE American: TMBR Key Takeaways 36 Rare, High Need Medical Dermatology Large Market Potential Multiple Shots on Goal De - Risked Portfolio Management Expertise • High unmet needs with large market potential • All strategic programs have been granted Orphan Drug status • No approved treatments for

  37. Slide 37: Investor contact information

    www.timberpharma.com For additional Investor Information please contact: John Koconis Stephanie Prince Chairman and CEO PCG Advisory jkoconis@timberpharma.com sprince@pcgadvisory.com (646) 863 - 6341 NYSE American: TMBR

Timber Pharmaceuticals — Investor Presentation (February 2023) on 6ix